» Articles » PMID: 32745300

Measurement Properties of the Product of Investigator's Global Assessment and Body Surface Area in Children and Adults with Atopic Dermatitis

Overview
Date 2020 Aug 4
PMID 32745300
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple clinician-reported outcome measures exist for atopic dermatitis (AD) severity. However, there is no gold standard for use in clinical practice.

Objectives: To determine the measurement properties of the product of validated Investigator's Global Assessment for AD (vIGA) and body surface area (BSA) overall or divided into six categories (cBSA: 0%/0.1, <10%/10, <30%/30, <50%/50, <70%/70 and <90%/90-100%) and compare with other clinician-reported and patient-reported outcomes in adults and children with AD.

Methods: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n = 653).

Results: vIGA*BSA and vIGA*cBSA had good convergent validity with BSA (Spearman's ρ = 0.97 and 0.93), eczema area and severity index (ρ = 0.94 and 0.92), and objective SCORAD (ρ = 0.88 and 0.89); and weak-to-good convergent validity with Numeric Rating Scale average itch (ρ = 0.22 and 0.22) and worst itch (ρ = 0.27 and 0.28), Patient-Oriented Eczema Measure (ρ = 0.44 and 0.43), Dermatology Life Quality Index (ρ = 0.48 and 0.49), ItchyQOL (ρ = 0.45 and 0.46), PROMIS Sleep Disturbance (ρ = 0.46 and 0.37) and sleep-related impairment (ρ = 0.31 and 0.31) in adults and/or children; very good discriminant validity for physician-reported global AD severity; good responsiveness to change of severity of AD and itch; and good reliability (intraclass correlation coefficient [95% confidence interval]: 0.72 [0.60-0.81] and 0.74 [0.62-0.82]) with no floor or ceiling effects. Thresholds for interpretability bands and clinically important difference were established.

Conclusions: vIGA*BSA and vIGA*cBSA scores showed good convergent and discriminant validity, reliability, responsiveness and interpretability in adults and children with AD, and were feasible for use in clinical practice. vIGA*BSA and vIGA*cBSA had slightly lower convergent validity than EASI or objective SCORAD, but might be more efficient to collect and score.

Citing Articles

Patient-reported outcome (PRO) instruments for disease severity and quality of life in patients with atopic dermatitis: a systematic review of English and Chinese literature.

Li A, Zhang M, Yang Y, Zhang J, Xie X, Li X Ann Transl Med. 2022; 10(16):906.

PMID: 36111032 PMC: 9469158. DOI: 10.21037/atm-22-3164.


The Meaning and Reliability of Minimal Important Differences (MIDs) for Clinician-Reported Outcome Measures (ClinROMs) in Dermatology-A Scoping Review.

Speeckaert R, Belpaire A, Herbelet S, Speeckaert M, van Geel N J Pers Med. 2022; 12(7).

PMID: 35887664 PMC: 9321211. DOI: 10.3390/jpm12071167.


Prevalence of Itch in German Schoolchildren: A Population-based Study.

Theodosiou G, Nissen T, Weisshaar E, Plachta-Danielzik S, Augustin M, Stander S Acta Derm Venereol. 2022; 102:adv00718.

PMID: 35393628 PMC: 9558745. DOI: 10.2340/actadv.v102.1063.


DESCRIBE-AD: A novel classification framework for atopic dermatitis.

Chovatiya R, Silverberg J J Am Acad Dermatol. 2021; 87(3):541-550.

PMID: 34774658 PMC: 10119387. DOI: 10.1016/j.jaad.2021.10.058.


IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.

Paller A, Tan J, Bagel J, Rossi A, Shumel B, Zhang H Br J Dermatol. 2021; 186(3):496-507.

PMID: 34726270 PMC: 9303952. DOI: 10.1111/bjd.20872.


References
1.
Gerbens L, Prinsen C, Chalmers J, Drucker A, von Kobyletzki L, Limpens J . Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2016; 72(1):146-163. DOI: 10.1111/all.12959. View

2.
Charman C, Venn A, Williams H . The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004; 140(12):1513-9. DOI: 10.1001/archderm.140.12.1513. View

3.
Metz C . Basic principles of ROC analysis. Semin Nucl Med. 1978; 8(4):283-98. DOI: 10.1016/s0001-2998(78)80014-2. View

4.
Leshem Y, Hajar T, Hanifin J, Simpson E . What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015; 172(5):1353-7. DOI: 10.1111/bjd.13662. View

5.
Koo T, Li M . A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016; 15(2):155-63. PMC: 4913118. DOI: 10.1016/j.jcm.2016.02.012. View